Due to its partial PPARγ agonist effect, telmisartan inhibits vascular ACE activity [13], AT-R1 expression [54, 55] and increases endothelial NO synthesis [56], preventing oxidative stress and endothelial dysfunction more effectively than non PPARγ-agonist ARBs [13]. Here, AGTR1 is linked to endothelial dysfunction.